Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer
1. In patients with estrogen receptor (ER)+ and human epidermal growth factor receptor 2 (HER2)- breast cancer, certain tumour microenvironments ...








